Saxenda (liraglutide 3.0 mg) is a once-daily GLP-1 receptor agonist licensed in the UK for weight management in adults and adolescents meeting specific criteria. Many patients wonder whether they can stop Saxenda for a week due to travel, illness, or other circumstances. Understanding the implications of treatment interruptions is essential for maintaining safe and effective weight management. This article examines what happens when Saxenda is paused, provides guidance on stopping and restarting the medication, and explains when to seek medical advice, all aligned with UK regulatory guidance from the MHRA and NICE.

Understanding Saxenda Treatment Continuity

Saxenda (liraglutide 3.0 mg) is a once-daily injectable medication licensed in the UK for weight management in adults with a BMI ≥30 kg/m², or ≥27-<30 kg/m² with at least one weight-related comorbidity. It is also licensed for weight management in adolescents aged ≥12 years with body weight >60 kg who meet specific criteria. As a glucagon-like peptide-1 (GLP-1) receptor agonist, Saxenda works by mimicking the action of the naturally occurring hormone GLP-1, which regulates appetite and food intake. The medication slows gastric emptying, increases feelings of fullness, and reduces hunger signals to the brain, thereby supporting calorie reduction and weight loss when combined with a reduced-calorie diet and increased physical activity.

For optimal therapeutic effect, Saxenda is designed to be administered consistently as part of a structured weight management programme. The treatment typically begins with a gradual dose escalation over five weeks, starting at 0.6 mg daily and increasing to the maintenance dose of 3.0 mg daily. This titration schedule helps minimise gastrointestinal side effects such as nausea and vomiting, which are among the most commonly reported adverse reactions. According to the MHRA-approved Summary of Product Characteristics (SmPC), daily dosing is recommended, and planned treatment breaks are not described in the guidance.

The pharmacokinetics of liraglutide show that it has a half-life of approximately 13 hours, meaning the medication is eliminated from the body relatively quickly after discontinuation. Consistency in dosing is important because the appetite-suppressing effects are dependent on maintaining therapeutic drug levels in the bloodstream. Interruptions to treatment, even brief ones, can affect the medication's efficacy and may influence your weight management progress.

Importantly, treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg dose if you have not lost at least 5% of your initial body weight, as continued treatment is unlikely to be beneficial.

What Happens If You Stop Saxenda for a Week

If you stop taking Saxenda for a week, several physiological changes occur as the medication is cleared from your system. Within 2-3 days of missing doses, liraglutide levels in your bloodstream will have substantially decreased, and by the end of a week, the drug will be largely eliminated from your body. This means the appetite-suppressing effects that help control hunger and reduce food intake will diminish progressively during this period.

The most immediate consequence is typically the return of appetite towards baseline levels. Appetite often returns as your body readjusts, which can make it challenging to maintain the dietary changes and calorie restriction that are essential components of your weight management plan. Some individuals may experience weight regain during even a short interruption, though the extent varies considerably between patients depending on their eating habits and activity levels during the break.

From a safety perspective, stopping Saxenda abruptly for a week does not typically cause dangerous withdrawal symptoms, as liraglutide is not associated with physical dependence. However, it's important to note that Saxenda is not licensed for glycaemic control. If you have type 2 diabetes and are using GLP-1 therapy for diabetes management, you should seek advice from your diabetes team before interrupting treatment, as it may affect your blood glucose control. Additionally, some patients experience a temporary worsening of gastrointestinal symptoms when restarting after a break.

The SmPC does not warn of specific risks from brief interruptions; the main issue is reduced efficacy and the potential need for re-titration when restarting. The primary concern remains the potential impact on your weight management progress and the need to potentially re-titrate the dose when restarting, which can delay your return to therapeutic effect.

Medical Guidance on Pausing Saxenda

Medical guidance advises against pausing Saxenda without clinical advice. The NICE technology appraisal (TA664) for liraglutide and the SmPC do not describe planned treatment breaks as part of the recommended regimen. If you are considering stopping Saxenda temporarily, it is essential to discuss this with your GP or specialist weight management service before making any changes to your prescribed regimen.

There are, however, legitimate medical circumstances that may necessitate temporary discontinuation of Saxenda. These include:

• Acute illness requiring hospitalisation or causing severe vomiting and dehydration

• Planned surgical procedures, where you should follow local perioperative policy and your healthcare team's advice

• Pregnancy or suspected pregnancy, as Saxenda is contraindicated during pregnancy

• Breastfeeding, as Saxenda is not recommended during breastfeeding

• Development of acute pancreatitis symptoms (severe, persistent abdominal pain)

• Severe gastrointestinal adverse effects that cannot be managed through dose adjustment

In such situations, your healthcare provider will assess the risks and benefits of continuing versus pausing treatment and provide specific guidance tailored to your circumstances. If you miss doses due to practical reasons such as forgetting your medication whilst travelling or running out of supplies, contact your prescriber or pharmacist promptly rather than simply extending the gap.

Remember that according to NICE guidance and the SmPC, Saxenda should be discontinued after 12 weeks on the 3.0 mg dose if you have not lost at least 5% of your initial body weight. This is an important treatment milestone that your healthcare provider will assess.

If a treatment break is necessary, maintain your dietary and physical activity modifications even when not taking the medication. Your healthcare team can provide strategies to help manage appetite and maintain progress during any necessary treatment breaks, ensuring that temporary discontinuation does not derail your overall weight management goals.

Restarting Saxenda After a Break

Restarting Saxenda after a break requires following specific guidance from the SmPC. The approach depends on how long you've been without the medication:

• If it has been 3 days or less since your last dose, you can resume at your previous dose

• If it has been more than 3 days since your last dose, you should reinitiate at 0.6 mg and follow the original titration schedule to gradually increase to 3.0 mg

This cautious approach to restarting after longer breaks helps minimise the risk of gastrointestinal side effects, particularly nausea, which can be more pronounced when restarting after a break. It's important to note that you should not take an extra dose to make up for a missed dose.

If you were still in the initial titration phase when you stopped, your prescriber will likely recommend restarting the titration schedule from the beginning if more than 3 days have passed. This ensures your body readjusts gradually to the medication's effects.

Practical considerations when restarting include:

• Contacting your prescriber before resuming to confirm the appropriate restart approach

• Being prepared for the possible return of initial side effects, particularly nausea

• Ensuring you have adequate supplies of the medication to avoid further interruptions

• Monitoring your response carefully during the first few days after restarting

• Maintaining your dietary and exercise modifications to support the medication's effects

Never restart Saxenda at a higher dose than recommended in the SmPC without explicit medical guidance, as this significantly increases the risk of adverse gastrointestinal effects. If you're unsure about how to restart, particularly if you experienced intolerance previously, contact your healthcare provider for personalised advice.

When to Contact Your Healthcare Provider

Prompt communication with your healthcare provider is essential in several scenarios related to stopping or interrupting Saxenda treatment. You should contact your GP, prescribing clinician, or specialist weight management service before intentionally stopping Saxenda for any planned reason, as they can provide personalised advice and help you understand the potential implications for your weight management programme.

Stop Saxenda and seek urgent medical attention if you experience any of the following:

• Severe, persistent abdominal pain that may radiate to the back, potentially indicating pancreatitis (call 999 or go to A&E)

• Persistent nausea and vomiting leading to dehydration or inability to maintain fluid intake (seek urgent medical care)

• Signs of allergic reaction, including rash, itching, difficulty breathing, or swelling of the face, lips, or throat (call 999 or go to A&E)

• Symptoms of gallbladder problems, such as pain in the upper right abdomen, fever, or yellowing of skin or eyes

• Rapid heartbeat or palpitations that are new or concerning

• Severe depression or suicidal thoughts (seek urgent help if these occur; reports of such effects are under review by regulatory authorities)

For less urgent concerns, contact your healthcare provider if you have missed multiple doses and are uncertain about how to restart, if you are experiencing significant weight regain during a treatment break, or if you are finding it difficult to adhere to the prescribed regimen for any reason. Your healthcare team can explore potential solutions, such as addressing side effects, providing additional support for adherence, or considering alternative approaches to weight management.

If you become pregnant or are planning pregnancy, stop Saxenda immediately and contact your healthcare provider, as the medication is contraindicated during pregnancy. Similarly, if you develop any new medical conditions or are prescribed new medications whilst taking Saxenda, inform your prescriber to ensure there are no contraindications or interactions that require treatment adjustment.

If you're unsure whether your symptoms require urgent attention, contact NHS 111 for advice. You can also report any suspected side effects to the MHRA through the Yellow Card Scheme (yellowcard.mhra.gov.uk or the Yellow Card app). Open communication with your healthcare team is fundamental to safe and effective weight management with Saxenda.

Frequently Asked Questions